Lv2
200 积分 2024-08-19 加入
Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD
4天前
已完结
Combating oxidative stress in non-alcoholic fatty liver disease: From mechanisms to therapeutic strategies
4天前
已完结
Bridging gut microbiota and renal health: Klotho as a promising therapeutic agent in DKD
4天前
已完结
Microbiota-targeted modulation of the gut–kidney axis in diabetic kidney disease: Therapeutic advances and future perspectives
4天前
求助中
The current findings on the gut-liver axis and the molecular basis of NAFLD/NASH associated with gut microbiome dysbiosis
5天前
已完结
Targeting gut microbiota in non-alcoholic fatty liver disease (NAFLD): Pathogenesis and therapeutic insights: A review
6天前
已完结
The current findings on the gut-liver axis and the molecular basis of NAFLD/NASH associated with gut microbiome dysbiosis
6天前
已完结
Advances in the acting mechanism and treatment of gut microbiota in metabolic dysfunction-associated steatotic liver disease
6天前
已完结
Mechanisms of hepatic and renal injury in lipid metabolism disorders in metabolic syndrome
10天前
已完结
Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis
13天前
已完结
皖公网安备34019202002308
